Cervical Cancer Diagnostics Market Size - By Diagnostic Methods (Pap Smear Tests, HPV DNA Tests, Colposcopy, Biopsy and Endocervical Curettage), Age Group (20-40 Years, Above 40 Years), End-use (Hospitals, Diagnostic Imaging Centres) & Forecast, 2024-2032

Cervical Cancer Diagnostics Market Size

Cervical Cancer Diagnostics Market size was valued at USD 7.2 billion in 2023 and is estimated to expand at over 5.3% CAGR from 2024 to 2032. Cervical cancer diagnostics refer to the various methods and procedures used to detect, diagnose, and evaluate cervical cancer or abnormalities in the cervix. Cervical cancer is one of the most common cancers among women worldwide. The increasing prevalence of cervical cancer, particularly in low and middle-income countries, is a significant catalyst for the market.
 

For instance, in 2020, the World Health Organization (WHO) reported over 604,000 new cases of cervical cancer globally, ranking it as the fourth most common cancer among women worldwide. Furthermore, the highest rates of cervical cancer incidence and mortality occur in low- and middle-income regions, including sub-Saharan Africa, Central America, and South-East Asia. Thus, as awareness of cervical cancer risks grows, more individuals seek screening and services related to cancer diagnostic, which is estimated to reach USD 324 billion by 2032.
 

Furthermore, technological advancements in cervical cancer diagnostics, including liquid-based cytology, HPV DNA testing, molecular diagnostics, and imaging modalities like colposcopy and fluorescence imaging, enhance the detection of precancerous lesions and early-stage cancers. These innovations improve screening test sensitivity and specificity, leading to better diagnostic accuracy. Moreover, they facilitate early intervention and treatment, resulting in improved patient outcomes.
 

Cervical Cancer Diagnostics Market Trends

Human papillomavirus (HPV) significantly increases the risk of cervical cancer. The growing prevalence of HPV infections, influenced by shifts in sexual behavior, inadequate vaccination coverage, and other such factors exacerbates the global burden of cervical cancer.
 

• With an improved understanding of the connection between HPV infection and cervical cancer, there is an increased focus on HPV testing within cervical cancer screening programs. This heightened emphasis stimulates the demand for diagnostic tests capable of detecting HPV DNA or RNA.
   
• Furthermore, governments, non-profit organizations, and healthcare agencies have launched various initiatives to raise awareness about cervical cancer and the importance of early detection.
   
• These efforts include educational campaigns, free or subsidized screening programs, and policy measures aimed at promoting routine screening among at-risk populations.
   
• For instance, the cervical cancer elimination initiative, spearheaded by the WHO, is a holistic strategy designed to eradicate cervical cancer as a public health concern. This initiative prioritizes vaccination, screening, and treatment, aiming to attain and sustain a minimal incidence rate of cervical cancer.
   
• Thus, the increased awareness has led to higher demand for diagnostic tests and services.
   

Cervical Cancer Diagnostics Market Analysis

The cervical cancer diagnostics industry, by diagnostic methods is categorized into pap smear tests, HPV DNA tests, colposcopy, biopsy and endocervical curettage, and other diagnostic methods. The pap smear segment garnered USD 2.9 billion revenue in 2023.
 

• The pap smear, a longstanding diagnostic tool, remains integral to cervical cancer screening programs worldwide due to its effectiveness in detecting abnormalities and precancerous changes in cervical cells.
   
• Furthermore, its inclusion in routine screening programs, accessibility, and affordability contribute to its widespread adoption across various healthcare settings.
   
• Moreover, the emphasis on early detection underscores the importance of pap smear testing in identifying cervical abnormalities promptly, thus stimulating demand and revenue within the segment.
   

Based on age group, the cervical cancer diagnostics market is segmented into 20-40 years, and above 40 years. The 20-40 years segment held over 84% of the market share in 2023.
 

• This dominance is fueled by several key factors, including the higher incidence rates of cervical cancer among women aged 20-40 due to various risk factors such as early sexual activity and exposure to HPV infection.
   
• Moreover, increased awareness campaigns and screening initiatives have encouraged greater participation in diagnostic testing within this age group.
   
• Additionally, proactive preventive healthcare behaviors and targeted interventions further contribute to the segment's market dominance.
   

Thus, as these trends persist, the 20-40 years age group is anticipated to maintain its significant share and witness continued growth in the market.
 

Based on end-use, the cervical cancer diagnostics market is segmented into diagnostic laboratories, hospitals, diagnostic imaging centers, cancer research institutes, and other end-users. The diagnostic laboratories segment accounted for 41.9% of the market share in 2023.
 

• These laboratories excel in specialized expertise and infrastructure tailored for cervical cancer diagnostics, offering comprehensive testing services such as pap smears and HPV DNA testing.
   
• Furthermore, they adhere to stringent quality assurance standards, ensuring reliable and accurate test results. With centralized facilities and collaborative partnerships with healthcare providers, diagnostic laboratories efficiently serve a broad patient base, meeting the increasing demand for cervical cancer screening and diagnostics.
   

Thus, as awareness of cervical cancer risks rises, the diagnostic laboratories segment is poised for continued growth in the market.
 

North America cervical cancer diagnostics market recorded around USD 2.9 billion in 2023.
 

• The growth is majorly owing to the region's relatively high prevalence of cervical cancer, prompting a significant demand for cervical cancer diagnostics in the region. For instance, according to the American Cancer Society's estimates, around 13,820 new cases of invasive cervical cancer are anticipated to be diagnosed in the U.S. in 2024. Additionally, approximately 4,360 women are expected to lose their lives due to cervical cancer during the same timeframe.
   
• Furthermore, the well-established healthcare infrastructure, coupled with a proactive approach towards adopting advanced diagnostic technologies, further fuels the market growth.
   
• Additionally, increased awareness about cervical cancer management and the availability of technologically advanced cervical cancer diagnostics contribute to their widespread adoption in North America.
   

Cervical Cancer Diagnostics Market Share

The cervical cancer diagnostics industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies is among a key market strategy. Some of the leading industry players including Abbott Laboratories, Becton, Dickinson and Company (BD), Hologic, Inc., QIAGEN, among others have a notable presence in the market.
 

Cervical Cancer Diagnostics Market Companies

Some of the eminent market participants operating in the cervical cancer diagnostics industry include:

• Abbott Laboratories
• Arbor Vita Corporation
• Becton, Dickinson and Company (BD)
• Danaher Corporation
• F. Hoffmann-La Roche Ltd
• Fujirebio Diagnostics, Inc.
• Hologic, Inc.
• QIAGEN
• Seegene Inc
• Thermo Fisher Scientific Inc.
   

Cervical Cancer Diagnostics Industry News

• In January 2024, BD and Techcyte, a leader in AI-based digital diagnostics, announced a collaboration to provide an AI-based algorithm guiding cytologists and pathologists in identifying evidence of cervical cancer and precancer through whole-slide imaging. The agreement empowered BD to offer a comprehensive solution, reducing human error and enhancing throughput in labs conducting pap tests, or pap smears, for standardized and efficient results. This collaboration aimed to provide a competitive edge to the company.
   
• In November 2023, the U.S. Food and Drug Administration (FDA) granted approval to Abbott for its molecular human papillomavirus (HPV) screening solution. This addition to the Alinity m family of diagnostic assays served as a robust cancer screening tool, specifically designed to detect high-risk HPV infections. The introduction of this product expanded the company's product portfolio and contributed to revenue growth.
   

The cervical cancer diagnostics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Diagnostic Methods

• Pap smear tests
• HPV DNA tests
• Colposcopy
• Biopsy and endocervical curettage
• Other diagnostic methods

Market, By Age Group

• 20-40 years
• Above 40 years

Market, By End-use

• Hospitals
• Diagnostic laboratories
• Diagnostic imaging centers
• Cancer research institutes
• Other end-users

The above information has been provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa